Novo Nordisk Makes $6.5 Billion Unsolicited Bid to Acquire Biotech Firm Metsera
Novo Nordisk has confirmed submitting an unsolicited proposal to acquire U.S.-based Metsera, Inc., a biotechnology company developing early- and mid-stage incretin and non-incretin…
Read More...
Read More...
